GlassScriptPhysician profile
John Magalhaes
NPI 1699851220
$40,491.55
in general payments reported to CMS, 2019-2025
22 companies · $5,076 in 2025
The $5,076 reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,483 · 2020: $15K · 2021: $3,639 · 2022: $3,737 · 2023: $1,559 · 2024: $6,617 · 2025: $5,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Food and Beverage | $2,001.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $36,885.42 | 2019-2025 | Cvi Contact Lens, Myday Contact Lens, Ortho-K Contact Lens |
| Sun Pharmaceutical Industries INC. | $917.29 | 2019-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $354.79 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $343.60 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $317.34 | 2022-2025 | Infuse, Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $315.92 | 2020-2023 | |
| Alcon Vision LLC | $275.39 | 2020-2025 | Tryptyr, Dailies Total1, Rocklatan |
| Abb Con-Cise Optical Group LLC | $230.84 | 2019 | |
| Abbvie INC. | $192.13 | 2022-2025 | |
| Oyster Point Pharma, INC. | $160.78 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $126.93 | 2021 | |
| Glaukos Corporation | $73.30 | 2022-2024 | Ce-Marked Kxla System |
| Shire North American Group INC | $58.39 | 2019 | |
| Apellis Pharmaceuticals, INC. | $51.54 | 2025 | Syfovre |
| Maculogix, INC. | $39.63 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $35.08 | 2025 | Xdemvy |
| Menicon America INC | $29.54 | 2019 | |
| Biotissue Holdings INC. | $24.83 | 2025 | |
| Tearlab Corp | $20.34 | 2022 | |
| Dompe US, INC. | $18.20 | 2025 | Oxervate |
| Allergan, INC. | $15.99 | 2022 | |
| Optos, INC. | $4.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Magalhaes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.